{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:55:30Z","timestamp":1790294130002,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T00:00:00Z","timestamp":1292976000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1007\/s00213-010-2113-3","type":"journal-article","created":{"date-parts":[[2010,12,21]],"date-time":"2010-12-21T04:11:07Z","timestamp":1292904667000},"page":"1-11","source":"Crossref","is-referenced-by-count":21,"title":["Second-generation antidepressants in social anxiety disorder: meta-analysis of controlled clinical trials"],"prefix":"10.1007","volume":"215","author":[{"given":"Gabriela Bezerra","family":"de Menezes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro Silva Freire","family":"Coutinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo F.","family":"Fontenelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Vigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Figueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcio","family":"Versiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,12,22]]},"reference":[{"key":"2113_CR1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1600-0447.1999.tb10845.x","volume":"100","author":"C Allgulander","year":"1999","unstructured":"Allgulander C (1999) Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 100:193\u2013198","journal-title":"Acta Psychiatr Scand"},{"key":"2113_CR2","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1176\/appi.ajp.161.9.1642","volume":"161","author":"C Allgulander","year":"2004","unstructured":"Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyad R, Kutcher SP, Clary CM (2004a) Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 161:1642\u20131649","journal-title":"Am J Psychiatry"},{"key":"2113_CR3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hup.602","volume":"19","author":"C Allgulander","year":"2004","unstructured":"Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, Emilien G (2004b) Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 19:387\u2013396","journal-title":"Hum Psychopharmacol"},{"key":"2113_CR4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1017\/S1461145706006602","volume":"10","author":"S Asakura","year":"2007","unstructured":"Asakura S, Tajima O, Koyama T (2007) Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol 10:263\u2013274","journal-title":"Int J Neuropsychopharmacol"},{"key":"2113_CR5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.175.2.120","volume":"175","author":"D Baldwin","year":"1999","unstructured":"Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M (1999) Paroxetine in social phobia\/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine study group. Br J Psychiatry 175:120\u2013126","journal-title":"Br J Psychiatry"},{"issue":"Suppl 17","key":"2113_CR6","first-page":"54","volume":"59","author":"JC Ballenger","year":"1998","unstructured":"Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Bobes J, Beidel DC, Ono Y, Westenberg HG (1998) Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 59(Suppl 17):54\u201360","journal-title":"J Clin Psychiatry"},{"key":"2113_CR7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/026988110201600412","volume":"16","author":"SD Barnett","year":"2002","unstructured":"Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR (2002) Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 16:365\u2013368","journal-title":"J Psychopharmacol"},{"key":"2113_CR8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/da.10096","volume":"18","author":"C Blanco","year":"2003","unstructured":"Blanco C, Schneier FR, Schmidt A, Blanco-Jerez CR, Marshall RD, Sanchez-Lacay A, Liebowitz MR (2003) Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety 18:29\u201340","journal-title":"Depress Anxiety"},{"key":"2113_CR9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1192\/bjp.179.1.23","volume":"179","author":"S Blomhoff","year":"2001","unstructured":"Blomhoff S, Haug TT, Hellstrom K, Holme I, Humble M, Madsbu HP, Wold JE (2001) Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 179:23\u201330","journal-title":"Br J Psychiatry"},{"issue":"6","key":"2113_CR10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50(6):683\u2013691","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"2113_CR11","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1037\/0022-006X.71.6.1058","volume":"71","author":"DM Clark","year":"2003","unstructured":"Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T, Davenport C, Louis B (2003) Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 71(6):1058\u20131067","journal-title":"J Consult Clin Psychol"},{"key":"2113_CR12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/01.jcp.0000106222.36344.96","volume":"24","author":"J Davidson","year":"2004","unstructured":"Davidson J, Yaryura-Tobias J, Dupont R, Stallings L, Barbato LM, van der Hoop RG, Li D (2004a) Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24:118\u2013125","journal-title":"J Clin Psychopharmacol"},{"key":"2113_CR13","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archpsyc.61.10.1005","volume":"61","author":"JR Davidson","year":"2004","unstructured":"Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM (2004b) Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 61:1005\u20131013","journal-title":"Arch Gen Psychiatry"},{"key":"2113_CR14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004714-199312000-00008","volume":"13","author":"JR Davidson","year":"1993","unstructured":"Davidson JR, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH (1993) Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 13:423\u2013428","journal-title":"J Clin Psychopharmacol"},{"key":"2113_CR15","volume-title":"Systematic reviews in medical care","author":"JJ Deeks","year":"2001","unstructured":"Deeks JJ, Altman DG, Bradburn MJ (2001) Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG (eds) Systematic reviews in medical care. BMJ Books, London"},{"key":"2113_CR16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.biopsych.2005.03.029","volume":"58","author":"T Furmark","year":"2005","unstructured":"Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S, Jacobsson E, Flyckt K, Grohp M, Bergstrom M, Pich EM, Nilsson LG, Bani M, Langstrom B, Fredrikson M (2005) Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 58:132\u2013142","journal-title":"Biol Psychiatry"},{"key":"2113_CR17","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archpsyc.1991.01810340070009","volume":"48","author":"CS Gelernter","year":"1991","unstructured":"Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ (1991) Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 48:938\u2013945","journal-title":"Arch Gen Psychiatry"},{"key":"2113_CR18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1468-2850.1997.tb00123.x","volume":"4","author":"RA Gould","year":"1997","unstructured":"Gould RA, Buckminster S, Pollack MH, Otto MW, Yap L (1997) Cognitive-behavioral and pharmacological treatment for social phobia: a meta-analysis. Clin Psychol Sci Pract 4:291\u2013306","journal-title":"Clin Psychol Sci Pract"},{"key":"2113_CR19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/YIC.0b013e3282f4224a","volume":"23","author":"RA Hansen","year":"2008","unstructured":"Hansen RA, Gaynes BN, Gartlehner G, Moore CG, Tiwari R, Lohr KN (2008) Efficacy and tolerability of second-generation antidepressants in social anxiety disorder. Int Clin Psychopharmacol 23:170\u2013179","journal-title":"Int Clin Psychopharmacol"},{"key":"2113_CR20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hup.989","volume":"24","author":"DW Hedges","year":"2009","unstructured":"Hedges DW, Brown BL, Shwalb DA (2009) A direct comparison of effect sizes from the clinical global impression-improvement scale to effect sizes from other rating scales in controlled trials of adult social anxiety disorder. Hum Psychopharmacol 24:35\u201340","journal-title":"Hum Psychopharmacol"},{"key":"2113_CR21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/0269881106065102","volume":"21","author":"DW Hedges","year":"2007","unstructured":"Hedges DW, Brown BL, Shwalb DA, Godfrey K, Larcher AM (2007) The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol 21:102\u2013111","journal-title":"J Psychopharmacol"},{"key":"2113_CR22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1017\/S1461145701002504","volume":"4","author":"RB Hidalgo","year":"2001","unstructured":"Hidalgo RB, Barnett SD, Davidson JR (2001) Social anxiety disorder in review: two decades of progress. Int J Neuropsychopharmacol 4:279\u2013298","journal-title":"Int J Neuropsychopharmacol"},{"key":"2113_CR23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"2113_CR24","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPT Higgins","year":"2008","unstructured":"Higgins JPT, Deeks JJ, Altman DG (2008) Special topics in statistics. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions. Wiley, West Sussex"},{"key":"2113_CR25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1586\/14737175.8.2.235","volume":"8","author":"JC Ipser","year":"2008","unstructured":"Ipser JC, Kariuki CM, Stein DJ (2008) Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother 8:235\u2013257","journal-title":"Expert Rev Neurother"},{"key":"2113_CR26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1192\/bjp.186.3.222","volume":"186","author":"S Kasper","year":"2005","unstructured":"Kasper S, Stein DJ, Loft H, Nil R (2005) Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186:222\u2013226","journal-title":"Br J Psychiatry"},{"issue":"Suppl 1","key":"2113_CR27","first-page":"11","volume":"62","author":"DJ Katzelnick","year":"2001","unstructured":"Katzelnick DJ, Greist JH (2001) Social anxiety disorder: an unrecognized problem in primary care. J Clin Psychiatry 62(Suppl 1):11\u201315, discussion 15\u20136","journal-title":"J Clin Psychiatry"},{"key":"2113_CR28","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1176\/ajp.152.9.1368","volume":"152","author":"DJ Katzelnick","year":"1995","unstructured":"Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC (1995) Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 152:1368\u20131371","journal-title":"Am J Psychiatry"},{"key":"2113_CR29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 62:617\u2013627","journal-title":"Arch Gen Psychiatry"},{"key":"2113_CR30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1017\/S0033291799008375","volume":"29","author":"RC Kessler","year":"1999","unstructured":"Kessler RC, Stang P, Wittchen HU, Stein M, Walters EE (1999) Lifetime co-morbidities between social phobia and mood disorders in the US national comorbidity survey. Psychol Med 29:555\u2013567","journal-title":"Psychol Med"},{"key":"2113_CR31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-200206000-00005","volume":"22","author":"KA Kobak","year":"2002","unstructured":"Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ (2002) Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 22:257\u2013262","journal-title":"J Clin Psychopharmacol"},{"key":"2113_CR32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.jcp.0000150227.61501.00","volume":"25","author":"KA Kobak","year":"2005","unstructured":"Kobak KA, Taylor LV, Warner G, Futterer R (2005) St. John\u2019s wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol 25:51\u201358","journal-title":"J Clin Psychopharmacol"},{"key":"2113_CR33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/da.20014","volume":"19","author":"M Lader","year":"2004","unstructured":"Lader M, Stender K, Burger V, Nil R (2004) Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 19:241\u2013248","journal-title":"Depress Anxiety"},{"issue":"Suppl 17","key":"2113_CR34","first-page":"33","volume":"59","author":"Y Lecrubier","year":"1998","unstructured":"Lecrubier Y (1998) Comorbidity in social anxiety disorder: impact on disease burden and management. J Clin Psychiatry 59(Suppl 17):33\u201338","journal-title":"J Clin Psychiatry"},{"key":"2113_CR35","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4088\/JCP.v65n0213","volume":"65","author":"U Lepola","year":"2004","unstructured":"Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L (2004) Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 65:222\u2013229","journal-title":"J Clin Psychiatry"},{"key":"2113_CR36","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4088\/JCP.v64n0708","volume":"64","author":"MR Liebowitz","year":"2003","unstructured":"Liebowitz MR, Demartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, Fayyad R, Clary CM (2003) Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 64:785\u2013792","journal-title":"J Clin Psychiatry"},{"key":"2113_CR37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archpsyc.62.2.190","volume":"62","author":"MR Liebowitz","year":"2005","unstructured":"Liebowitz MR, Gelenberg AJ, Munjack D (2005a) Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 62:190\u2013198","journal-title":"Arch Gen Psychiatry"},{"key":"2113_CR38","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4088\/JCP.v66n0213","volume":"66","author":"MR Liebowitz","year":"2005","unstructured":"Liebowitz MR, Mangano RM, Bradwejn J, Asnis G (2005b) A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 66:238\u2013247","journal-title":"J Clin Psychiatry"},{"key":"2113_CR39","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/archpsyc.49.4.290","volume":"49","author":"MR Liebowitz","year":"1992","unstructured":"Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, Et AL (1992) Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 49:290\u2013300","journal-title":"Arch Gen Psychiatry"},{"key":"2113_CR40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4088\/JCP.v63n0113","volume":"63","author":"MR Liebowitz","year":"2002","unstructured":"Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD (2002) A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 63:66\u201374","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 1","key":"2113_CR41","first-page":"17","volume":"62","author":"RB Lydiard","year":"2001","unstructured":"Lydiard RB (2001) Social anxiety disorder: comorbidity and its implications. J Clin Psychiatry 62(Suppl 1):17\u201323, discussion 24","journal-title":"J Clin Psychiatry"},{"key":"2113_CR42","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/01.jcp.0000186871.04984.8d","volume":"25","author":"M Muehlbacher","year":"2005","unstructured":"Muehlbacher M, Nickel MK, Nickel C, Kettler C, Lahmann C, Pedrosa Gil F, Leiberich PK, Rother N, Bachler E, Fartacek R, Kaplan P, Tritt K, Mitterlehner F, Anvar J, Rother WK, Loew TH, Egger C (2005) Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 25:580\u2013583","journal-title":"J Clin Psychopharmacol"},{"key":"2113_CR43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004714-199908000-00010","volume":"19","author":"AC Pande","year":"1999","unstructured":"Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM (1999) Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19:341\u2013348","journal-title":"J Clin Psychopharmacol"},{"key":"2113_CR44","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.jcp.0000138764.31106.60","volume":"24","author":"K Rickels","year":"2004","unstructured":"Rickels K, Mangano R, Khan A (2004) A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 24:488\u2013496","journal-title":"J Clin Psychopharmacol"},{"key":"2113_CR45","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1176\/ajp.156.5.756","volume":"156","author":"MB Stein","year":"1999","unstructured":"Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B (1999) Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 156:756\u2013760","journal-title":"Am J Psychiatry"},{"key":"2113_CR46","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.280.8.708","volume":"280","author":"MB Stein","year":"1998","unstructured":"Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I (1998) Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 280:708\u2013713","journal-title":"JAMA"},{"key":"2113_CR47","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00213-004-1957-9","volume":"177","author":"MB Stein","year":"2005","unstructured":"Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM (2005) Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 177:280\u2013288","journal-title":"Psychopharmacology (Berl)"},{"key":"2113_CR48","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(08)60488-2","volume":"371","author":"MB Stein","year":"2008","unstructured":"Stein MB, Stein DJ (2008) Social anxiety disorder. Lancet 371:1115\u20131125","journal-title":"Lancet"},{"key":"2113_CR49","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.pnpbp.2007.06.027","volume":"31","author":"S Vaishnavi","year":"2007","unstructured":"Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JR (2007) Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 31:1464\u20131469","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2113_CR50","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4088\/JCP.v68n0215","volume":"68","author":"M Ameringen van","year":"2007","unstructured":"van Ameringen M, Mancini C, Oakman J, Walker J, Kjernisted K, Chokka P, Johnston D, Bennett M, Patterson B (2007) Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. J Clin Psychiatry 68:288\u2013295","journal-title":"J Clin Psychiatry"},{"key":"2113_CR51","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1176\/appi.ajp.158.2.275","volume":"158","author":"MA Ameringen van","year":"2001","unstructured":"van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, Johnston DG, Lavallee YJ, Nandy S, Pecknold JC, Hadrava V, Swinson RP (2001) Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 158:275\u2013281","journal-title":"Am J Psychiatry"},{"key":"2113_CR52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0924-977X(92)90032-4","volume":"2","author":"IM Vliet van","year":"1992","unstructured":"van Vliet IM, Den Boer JA, Westenberg HG (1992) Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 2:21\u201329","journal-title":"Eur Neuropsychopharmacol"},{"key":"2113_CR53","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02244762","volume":"115","author":"IM Vliet van","year":"1994","unstructured":"van Vliet IM, Den Boer JA, Westenberg HG (1994) Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 115:128\u2013134","journal-title":"Psychopharmacology (Berl)"},{"key":"2113_CR54","first-page":"167","volume":"46","author":"M Versiani","year":"1997","unstructured":"Versiani M, Nardi AE, Figueira I, Mendlowicz M, Marques C (1997) Double-blind placebo controlled trial with bromazepam in social phobia. J Bras Psiquiatr 46:167\u2013171","journal-title":"J Bras Psiquiatr"},{"key":"2113_CR55","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1192\/bjp.161.3.353","volume":"161","author":"M Versiani","year":"1992","unstructured":"Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R (1992) Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 161:353\u2013360","journal-title":"Br J Psychiatry"},{"issue":"Suppl 17","key":"2113_CR56","first-page":"20","volume":"59","author":"HG Westenberg","year":"1998","unstructured":"Westenberg HG (1998) The nature of social anxiety disorder. J Clin Psychiatry 59(Suppl 17):20\u201326","journal-title":"J Clin Psychiatry"},{"key":"2113_CR57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.jcp.0000104906.75206.8b","volume":"24","author":"HG Westenberg","year":"2004","unstructured":"Westenberg HG, Stein DJ, Yang H, Li D, Barbato LM (2004) A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24:49\u201355","journal-title":"J Clin Psychopharmacol"},{"key":"2113_CR58","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0193-953X(05)70254-9","volume":"24","author":"HU Wittchen","year":"2001","unstructured":"Wittchen HU, Fehm L (2001) Epidemiology, patterns of comorbidity, and associated disabilities of social phobia. Psychiatr Clin North Am 24:617\u2013641","journal-title":"Psychiatr Clin North Am"},{"key":"2113_CR59","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1017\/S0033291798008174","volume":"29","author":"HU Wittchen","year":"1999","unstructured":"Wittchen HU, Stein MB, Kessler RC (1999) Social fears and social phobia in a community sample of adolescents and young adults: prevalence, risk factors and co-morbidity. Psychol Med 29:309\u2013323","journal-title":"Psychol Med"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-010-2113-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-010-2113-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-010-2113-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T15:28:54Z","timestamp":1685892534000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-010-2113-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,22]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["2113"],"URL":"https:\/\/doi.org\/10.1007\/s00213-010-2113-3","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,22]]}}}